Bank of New York Mellon’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Bank of New York Mellon’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13,308	Closed	-$50K	–	4502
2021 Q1	$50K	Buy	+13,308	New	+$57.8K	﹤0.01%	4263
2019 Q4	–	Sell	-3,009	Closed	-$32K	–	4252
2019 Q3	$32K	Sell	3,009 -361	-11%	-$4.72K	﹤0.01%	4154
2019 Q2	$57K	Sell	3,370 -13,452	-80%	-$364K	﹤0.01%	4106
2019 Q1	$567K	Buy	16,822 +910	+6%	+$30.4K	﹤0.01%	3491
2018 Q4	$465K	Sell	15,912 -68	-0.4%	-$3.02K	﹤0.01%	3524
2018 Q3	$985K	Buy	15,980 +1,015	+7%	+$68.7K	﹤0.01%	3265
2018 Q2	$1.1M	Buy	14,965 +4,021	+37%	+$313K	﹤0.01%	3199
2018 Q1	$718K	Buy	10,944 +92	+0.8%	+$6.95K	﹤0.01%	3393
2017 Q4	$912K	Sell	10,852 -1,216	-10%	-$119K	﹤0.01%	3305
2017 Q3	$1.39M	Sell	12,068 -209	-2%	-$22K	﹤0.01%	3027
2017 Q2	$1.43M	Buy	12,277 +2,684	+28%	+$333K	﹤0.01%	3034
2017 Q1	$1.18M	Buy	9,593 +93	+1%	+$12.2K	﹤0.01%	3148
2016 Q4	$1.29M	Buy	9,500 +861	+10%	+$153K	﹤0.01%	3115
2016 Q3	$1.72M	Buy	8,639 +404	+5%	+$69.6K	﹤0.01%	2851
2016 Q2	$1.07M	Buy	8,235 +2,454	+42%	+$273K	﹤0.01%	3093
2016 Q1	$541K	Buy	5,781 +1,269	+28%	+$138K	﹤0.01%	3402
2015 Q4	$914K	Sell	4,512 -430	-9%	-$76.9K	﹤0.01%	3229
2015 Q3	$719K	Buy	4,942 +950	+24%	+$174K	﹤0.01%	3385
2015 Q2	$849K	Buy	3,992 +1,642	+70%	+$403K	﹤0.01%	3430
2015 Q1	$544K	Buy	+2,350	New	+$568K	﹤0.01%	3575

Other funds holding BLCM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Bank of New York Mellon's BLCM Position: Q2 2021 in Review

Bank of New York Mellon sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2021, closing a stake of 13,308 shares — an estimated $50K sold.

Bank of New York Mellon first reported a position in BLCM in Q1 2015 and held it in 20 quarters. The position peaked at $1.72M in Q3 2016. 30 funds tracked by Wall St. Rank hold BLCM as of Q2 2021.

Bank of New York Mellon reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Bank of New York Mellon sold 13,308 Bellicum Pharmaceuticals, Inc. shares in Q2 2021, an estimated $50K.
Bank of New York Mellon first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 20 quarters.
Bank of New York Mellon's Bellicum Pharmaceuticals, Inc. position peaked at $1.72M in Q3 2016.
30 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2021.

Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.